Entyvio®

INN: vedolizumab

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Originator Biologic

Delivery Route

Intravenous Infusion
Subcutaneous Injection

Health Canada Approval

2015

Storage

Refrigerate between 2 and 8°C, keep in original carton to protect from light, if needed the syringe can be left a room temperature for up to seven days, do not freeze, do not use after expiry date, do not use if you notice any particles or discolouration in the liquid prior to administration.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

Effects not studied; women of reproductive potential recommended to use contraception during treatment and for at least 18 weeks after last dose.

Breastfeeding Indication

Effects unknown; please consult your doctor.

Pediatric Indication

Not recommended for use in children or adolescents (under 18 years of age).

Learn More

View the Entyvio® product monograph.